Moreover, CD28-mediated T cell co-stimulation has been shown to be crucial for PD-1 therapy in cancer patients as loss of CD28 via T cell exhaustion was shown to correlate to clinical irresponsiveness towards PD-1 ICI (37). The gene discussed is CD28; the disease is cancer.